Team

Chia Chia advises senior pharmaceutical and biotech executives in therapeutic areas such as CNS, oncology and immunology. She works with business development and disease area leaders to identify and evaluate in-licensing opportunities, and develop product and disease strategy. As VP of SHI Consulting, she has assisted in commercial strategy for billion dollar products and pharma's top disease franchises. Her clientele includes the corporate headquarters of pharma such as BMS, Wyeth, as well as public biotech companies in North America and Europe. As President of SHI Link, she leverages her extensive contacts and knowledge of product opportunities to assist her clients in identifying partners and in-licensing candidates in diverse therapeutic areas.

Building on executive operating roles in leading pharma and biotech companies for over a decade, Gardiner is focused on consummating major transactions which span creative alliance structures, stages of development and a variety of technology innovations. In addition to leading over a dozen successful transactions between biotech and pharma companies, including with Human Genome Sciences, Memory Pharmaceuticals, Roche, GSK and Amgen, he has led the execution of an equal number of biotech-biotech alliances between product, antibody, and platform companies such as Affymetrix and Cambridge Antibody Technologies. The total potential up front and milestone value of buy-side and sell-side transactions in which he's had a leading role in over the last ten years exceeds $750 MM, excluding royalties. Additionally, he has been part of the transaction team for large acquisitions, such as the Glaxo purchase of Affymax for $530 MM.

Borys is the President and Founder of SHI Consulting and the Chairman of SHI Capital. He specializes in strategic planning, fund raising and business development for private and public biotech, medical device, and imaging companies. In the past 10 years, he has worked closely with industry leaders, Top 10 pharmaceutical companies, governments, hospitals and health care networks. He also provided interim management for 7 start-ups and has acted as an angel investor for 10 companies. He is currently a member of a number of for-profit and not-for-profit boards, including the advisory boards of the Singapore Cancer Syndicate, Medical and Related Sciences Commercialization Centre (Toronto), GEMMA Biotechnology, Duravest, Estracure, and an Industrial Policy Advisory Committee (IPAC) for a large multinational pharmaceutical company.

As the Vice President of SHI Link, Dr. John McGraw works extensively with pharmaceutical and mid-size biotechnology companies in the areas of product evaluation, licensing, commercialization and therapeutic area assessment. John's in-depth knowledge of therapeutic areas such as inflammation, CNS and oncology, combined with his business expertise, has enabled him to manage projects related to product assessment for therapeutic re-profiling, product acquisition and the identification of licensing opportunities. John has also worked on projects related to clinical development, corporate strategy and research potential for leading pharma and biotech companies. Prior to joining SHI Link, John worked as a Senior Consultant at SHI Consulting and founded his own medical device company. He received his Ph.D. in neuroscience from the University of British Columbia, Canada.

Maryam has worked extensively in the areas of product evaluation, therapeutic area assessment, and licensing. With her depth of knowledge in inflammation, immunology, transplantation, and autoimmunity combined with her business expertise, she has managed projects related to product and therapeutic area assessment and identification of licensing/acquisition opportunities. Having worked in medical affairs and life-cycle management, she is also experienced in assessing competitive landscape, market needs, life cycle management issues, defining pre-market awareness for disease states, and developing and executing pre/post-launch strategy to meet product objectives. Maryam obtained her Ph.D. in transplantation immunology and MBA in marketing/strategic management. She has also received two post-doctoral training in autoimmunity and stem cell transplantation in Canada and Europe prior to commencing her career in the pharmaceutical industry.

Tetyana has appraised prospective drug candidates in multiple stages of development for multinational and mid sized pharmaceutical companies in autoimmune, respiratory and cardiovascular therapeutic areas. As an Analyst at SHI Consulting, Tetyana has assessed current and future treatment trends within the inflammation landscape and took part in formulating clinical strategies for multinational pharma. As Business Development Manager at SHI Link, Tetyana researches new markets and partners for clients aiming to expand clinical and marketing reach. Tetyana received her MSc in cardiovascular research from the University of Toronto, Canada.